Quality Hits at Lightning Speed
Unleash accelerated hit identification with Evotec’s high-throughput screening.
Drug discovery is a fundamental aspect of the pharmaceutical industry that requires meticulous research and experimentation. One critical step in drug discovery is hit identification, the process of finding chemically attractive small molecules that show a desirable biological profile.
The first four parts of the series are available on-demand. Our latest episode on High Content Imaging (#5) will soon be available on demand as well.
Pt 1 - High Throughput Screening Strategies - Available On-Demand
Unlocking High Throughput Hit Identification Strategies
In today's dynamic landscape of drug discovery, the quest for high-quality chemical starting points is paramount.
Join us as Dr. Thomas Ahrens, Group Leader, Hit ID & Biophysics at Evotec, shares invaluable insights into the innovative strategies driving high throughput screening (HTS) processes.
The Q&A session is joined by Dr. Helene Jousset Sabroux, Group leader, High Throughput Biology & Screening at Evotec.
During this engaging session, you'll gain:
- In-depth understanding of the HTS process at Evotec.
- Insights into the challenges posed by today's HTS landscape.
- Strategies for mitigating risks in drug discovery projects.
- A glimpse into Evotec's approach to delivering the best compound starting points to our partners.
Get to Know Our Speaker
Pt 2 - Protein Sciences - Available On-Demand
It All Starts With a Protein – Protein Sciences as a Key to Success in Drug Discovery
At Evotec, we believe that we are living in a golden age of technological advances, with breakthrough technologies in AI/ML, screening, structural biology, biophysics and beyond. Together with our partners, we support various drug discovery programs and getting the right protein is often critical for success.
Join us as Dr. James Errey, VP, Head of Global Protein Production, discusses the innovative technologies driving protein reagent generation for drug discovery at Evotec. James will share a range of case studies providing practical insights and real-world applications of GPCR structural biology, protein biologics, membrane protein biophysics and high-throughput screening.
Get to Know Our Speaker
Pt 3 - Biophysics - Available On-Demand
Molecular Interactions Matter - Biophysical Screening for Early Drug Discovery
Evotec’s biophysics platform supports drug discovery projects in the use of sophisticated binding and functional techniques to measure the molecular interactions between initial hit compounds and their targets with high throughput, accuracy, and precision. A growing range of biophysical techniques are specifically applied during hit identification.
Join us as Dr. Florian Krieger, VP Biophysics, presents Evotec’s most recent developments in biophysical screening approaches during early drug discovery stages, including an introduction to Evotec’s library sets suitable for biophysical screening. Florian will further discuss case studies covering lead-like screening, fragment-based approaches, and covalent hit identification.
Get to Know Our Speaker
Pt 4 - Integr. Structural Biology - Available On-Demand
The Role of Structural Insights in Drug Discovery
Structural information plays a pivotal role in drug discovery, and access to 3D information can streamline many aspects across the value chain.
Dr. Jay Bertrand, Vice President, Head of Global Structural Biology and Evotec's Princeton Site Head, discusses the evolution of structural support to drug discovery projects, and provides insight into choosing the right protein for structural analysis. He will also share case studies on the application of X-ray and cryo-EM to obtain compound-bound protein structures.
Get to Know Our Speaker
Pt 5 - High Content Imaging - Available On-Demand
Illuminating Cellular Processes Through High Content Methods - The Power of Cell Painting in Drug Discovery
Dr. Karsten Kottig, VP Imaging & Analysis and Dr. Sven Schreiter, Senior Research Scientist High-Throughput Screening, share insights into Evotec's high content imaging capabilities, and explain the basic concept of Cell Painting and its usage as a phenotypic platform across drug discovery phases.
